Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health onychomycosis testing Coverage | Open…
    Ask Trek AI about this page
    CurrentOscar HealthPolicy N/A

    Onychomycosis diagnostic testing and coverage

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage and limitations for laboratory and diagnostic testing used to diagnose or confirm onychomycosis (tinea unguium) and describes related testing technologies; applies to Oscar Health providers and claims processing.

    Policy Summary
    PayerOscar Health
    PolicyOnychomycosis diagnostic testing and coverage
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionObtain and document confirmatory laboratory testing (eg, KOH, PAS, or fungal culture) before initiating treatment.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    51Total refs
    95%PAS sensitivity
    60%KOH/culture sensitivity
    5.5%Global prevalence
    96,293Large cohort

    Coverage criteria for diagnostic testing

    Initial and secondary diagnostic testing

    Covered when the following are met

    Diagnostic tests meeting criteria: Direct microscopic examination with potassium hydroxide (KOH), fungal culture of desquamated subungual material, or fungal stain of nail clipping(s) MEETS CRITERIA.

    Supported by policy III. Indications and/or Limitations of Coverage and Notes

    NAAT after therapy failure: For individuals with onychomycosis for whom antifungal therapy has failed to resolve infection, nucleic acid amplification testing (NAAT) MEETS CRITERIA (see Note 1 for examples of NAAT methods and organisms tested).

    Supported by policy III. Indications and/or Limitations of Coverage and Note 1

    Tests considered not meeting criteria

    Not covered for screening/confirmation in asymptomatic or initial diagnosis

    NAAT not for initial diagnosis/screening: To screen for, diagnose, or confirm onychomycosis, NAAT (eg, PCR, PCR-RFLP, next-generation sequencing) DOES NOT MEET CRITERIA (except when used after antifungal therapy failure as specified elsewhere).

    Policy III and Note 1

    ATR-FTIR not covered: To screen for, diagnose, or confirm onychomycosis, attenuated total-reflectance Fourier transform infrared (ATR-FTIR) spectroscopy DOES NOT MEET CRITERIA due to insufficient published evidence.

    Policy III

    Fungal sterol testing not covered: Testing for the presence of fungal-derived sterols (eg, ergosterol) DOES NOT MEET CRITERIA for screening, diagnosis, or confirmation of onychomycosis due to lack of sufficient published scientific literature supporting clinical benefit.

    Policy III

    Confirmatory diagnostic testing

    Covered when laboratory confirmation is obtained prior to treatment, per guideline recommendations

    Confirmatory testing before treatment: Laboratory confirmation of a clinical diagnosis of onychomycosis should be obtained before starting treatment; this helps exclude non-fungal nail disease, detect mixed infections, and identify less-responsive forms of infection.

    BAD guidance (BAD recommendations cited)

    Acceptable confirmatory tests: Acceptable methods include KOH preparation/direct microscopy, fungal culture, periodic acid-Schiff (PAS) staining of nail clippings, and PCR; choice may depend on need for species identification, cost, turnaround time, and clinical context (PCR noted as useful but less cost-effective for general use).

    AAFP, JDD, BAD guidance

    Specimen handling: Obtain subungual debris and multiple nail clippings from the most proximal area of onycholysis; clean the nail with 70% isopropyl alcohol prior to collection; consider trimming the nail plate to access proximal material when necessary.

    AAFP specimen collection guidance

    NAAT (nucleic acid amplification testing), ATR-FTIR (attenuated total-reflectance Fourier transform infrared spectroscopy), and testing for fungal-derived sterols (e.g., ergosterol) are not indicated for routine screening, initial diagnosis, or confirmation of onychomycosis. The policy explicitly states that these methods DO NOT MEET CRITERIA for screening, diagnosis, or confirmation, except that NAAT may be considered when antifungal therapy has failed to resolve infection.

    PCR-based NAAT methods can detect fungal DNA from nonviable organisms or environmental/nonpathogenic fungi; the BAD guidance notes that PCR "may detect nonpathogenic or dead fungus, which could limit its use in identifying the true pathogen," representing a limitation when interpreting positive NAAT results for clinical decision-making.

    The references and publication-history sections list the evidence base supporting the policy (51 references) and the policy's governance approval date, but they do not contain any additional explicit exclusions beyond those stated in the coverage criteria. The publication history documents the policy's original documentation and approval on 06/16/2026.

    The policy describes NAAT, ATR-FTIR spectroscopy, and ergosterol/sterol testing as not meeting criteria for use to screen for, diagnose, or confirm onychomycosis because of insufficient published literature demonstrating they are required and beneficial. NAAT is an exception when used after failed antifungal therapy, where it MEETS CRITERIA.

    Because different tests show variable positivity and performance characteristics, the policy emphasizes obtaining confirmatory testing prior to initiating treatment. Studies cited include Caldwell et al. (demonstrating discordance between PCR and PAS) and larger retrospective data (Gupta et al.) supporting routine laboratory confirmation; BAD guidance also recommends confirmatory testing to exclude non-fungal nail disease and detect mixed or less responsive infections.

    The cited reference lists and publication-history excerpts included in the document do not state conditions that are explicitly labeled as not medically necessary beyond the exclusions found in the 'Indications and/or Limitations of Coverage' section.

    Applicable procedure and lab codes

    Applicable CPT/HCPCS Procedure CodesCPT
    82542Column chromatography, includes mass spectrometry, if performed (eg, HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen
    87101Culture, fungi (mold or yeast) isolation, with presumptive identification of isolates; skin, hair, or nail
    87149Culture, typing; identification by nucleic acid (DNA or RNA) probe, direct probe technique, per culture or isolate, each organism probed
    87150Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed
    87153Culture, typing; identification by nucleic acid sequencing method, each isolate (eg, sequencing of the 16S rRNA gene)
    87205Smear, primary source with interpretation; Gram or Giemsa stain for bacteria, fungi, or cell types
    87206Smear, primary source with interpretation; fluorescent and/or acid fast stain for bacteria, fungi, parasites, viruses or cell types
    87220Tissue examination by KOH slide of samples from skin, hair, or nails for fungi or ectoparasite
    87480Infectious agent detection by nucleic acid (DNA or RNA); Candida species, direct probe technique
    87481Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique
    1–10 of 14
    1/2

    Provider responsibilities and billing guidance

    Prior Authorization

    Verify member benefits and government policy overrides

    Coverage and other determinations apply only when the service is a covered benefit for the member at the time of request; Medicare and Medicaid policies (LCD/NCD and state Medicaid rules) supersede this policy when in conflict. Providers should verify member benefits and applicable government policies before proceeding.

    • Application of criteria depends on individual benefit coverage at request time
    • Government policies (LCD/NCD) supersede when in conflict
    Billing Rule

    Use applicable CPT/HCPCS codes for diagnostic tests

    Use the policy's listed CPT/HCPCS procedure codes when submitting claims for diagnostic testing; these codes may be used in billing and prior authorization reviews and payer processes.

    Clinical background on onychomycosis

    Background: Onychomycosis (tinea unguium) is a fungal infection of the nail most commonly caused by dermatophytes (for example, Trichophyton species), though yeasts and nondermatophyte molds can also be responsible. Toenails are affected more often than fingernails. Risk factors include older age, diabetes, immunosuppression, and activities that increase nail trauma. Clinical diagnosis should be supported by laboratory confirmation (eg, KOH, culture, PAS histology), and the policy references guidance recommending specimen collection from dystrophic or discolored nail areas to maximize diagnostic yield.

    Key terms and test definitions

    NAAT (Nucleic Acid Amplification Testing) definition
    DefinitionNucleic acid amplification testing (NAAT) — molecular methods that detect fungal nucleic acid sequences (examples listed: PCR, PCR-RFLP, next-generation sequencing [NGS]).
    ExamplesPolymerase chain reaction (PCR); PCR–restriction fragment length polymorphism (PCR-RFLP); next-generation sequencing (NGS).
    PurposeUsed to detect and identify fungal species by amplifying and analyzing DNA/RNA targets from nail or subungual specimens.
    KOH definition
    DefinitionKOH — potassium hydroxide direct microscopic examination of nail material (KOH preparation) to visualize fungal elements.
    SpecimenTypically performed on subungual debris or nail clippings collected from the affected nail(s).
    Policy Summary
    PayerOscar Health
    PolicyOnychomycosis diagnostic testing and coverage
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionObtain and document confirmatory laboratory testing (eg, KOH, PAS, or fungal culture) before initiating treatment.
    SourceLink
    On This Page
    Coverage criteria for diagnostic testingApplicable procedure and lab codesProvider responsibilities and billing guidanceClinical background on onychomycosisKey terms and test definitions
    • Applicable CPT/HCPCS codes listed in section VIII (see chunks 34–35)
    • Government policies or LCD/NCD may override payer coding requirements
    Prior Authorization

    No prior authorization rules specified here — confirm with payer

    This excerpt does not list any specific prior authorization requirements or identify which services require preauthorization. Providers should follow member benefit documents and payer-specific prior authorization processes.

    • Policy section shown provides evidence and guidance but no explicit prior auth rules in these chunks
    • Check member benefit documents and payer portals for prior authorization requirements
    Note

    Choose therapy informed by diagnostic confirmation

    Select antifungal therapy based on diagnostic confirmation and clinical context; treatment options include topical agents, oral antifungals, and other modalities noted in guidelines.

    • Therapies include topical agents (tavaborole, efinaconazole), oral antifungals (terbinafine, itraconazole, fluconazole), and adjunctive therapies (laser, iontophoresis)
    • If nail matrix is involved, consider combining systemic and topical therapy
    Step Therapy

    Empiric terbinafine may be used if testing cost-prohibitive

    AAFP states empiric terbinafine can be considered when testing is cost prohibitive; however, laboratory confirmation is generally recommended before initiating treatment.

    • AAFP: "Diagnostic testing is generally recommended before initiating treatment, but empiric treatment with terbinafine can be considered if testing is cost prohibitive."
    • Accurate diagnosis requires identification of physical changes and positive laboratory analysis
    Note

    No step-therapy rules specified in this section

    No step therapy or sequencing requirements are specified in these policy excerpts. Providers should follow clinical judgment and payer-specific utilization management rules if present.

    • Policy excerpts do not define step therapy algorithms or required treatment sequences
    • Follow payer-specific rules where applicable
    Documentation Required

    Document clinical findings and mycologic confirmation

    Providers must submit accurate documentation and appropriate coding for services performed; an onychomycosis diagnosis should be supported by clinical findings and mycological laboratory results.

    • Submit documentation according to industry standards (CPT, ICD-10, UB, CMS/NCCI rules)
    • Diagnosis should be based on clinical exam plus mycological lab results (KOH, culture, PAS, PCR as appropriate)
    Documentation Required

    Collect and document appropriate nail specimens prior to testing

    Follow guideline specimen collection recommendations and document collection technique: clean the nail with 70% isopropyl alcohol and obtain subungual debris and multiple nail clippings from the most proximal area of onycholysis.

    • Clean nail with 70% isopropyl alcohol prior to collection (AAFP guidance)
    • Obtain subungual debris and multiple nail clippings from the most proximal area of onycholysis
    • Document specimen source and collection method in the medical record
    Documentation Required

    Include confirmatory lab test results and literature-based rationale

    Retain and attach supporting diagnostic documentation referenced in guidelines and evidence when submitting claims: KOH microscopy, fungal culture, PAS histology, and when used, PCR or sequencing results.

    • Cite KOH, culture, PAS as core confirmatory tests per BAD, AAFP, and cited literature
    • If PCR/NAAT used (eg, after therapy failure), include test results and rationale
    Denial Risk

    Risk of claim denial or recoupment for incorrect coding or documentation

    Claims may be denied or recouped if coding/billing guidelines, current reimbursement policies, or documentation requirements are not followed; ensure correct codes and supporting documentation are submitted.

    • Failure to follow coding/billing guidelines or provide accurate documentation may result in denial or recoupment
    • Use the listed CPT/HCPCS codes and document medical necessity and test results
    Note

    No additional provider actions in this excerpt

    This specific section of the document does not include additional actionable items beyond those already stated in these provider actions.

    • No further provider actions are present in these chunks
    Denial Risk

    No explicit denial triggers listed here

    No explicit denial triggers are present in these chunks beyond general coding/documentation risks; follow documentation and coding rules to reduce denial risk.

    • No specific denial triggers listed in these excerpts
    • Adhere to documentation and coding guidance to avoid denials
    RoleRapid, low-cost initial laboratory method to detect fungal hyphae or yeast cells as part of confirmatory testing for onychomycosis.
    Onychomycosis definition
    DefinitionOnychomycosis — the technical term for a fungal nail infection (tinea unguium).
    Common causesMost commonly caused by dermatophytes (eg, Trichophyton spp.) but may also be due to yeasts or nondermatophyte molds.
    Affected sitesCan affect fingernails or toenails, with toenail involvement being more common.
    Confirmatory testing definition
    DefinitionConfirmatory testing — laboratory methods used to establish the presence of fungal infection prior to initiating therapy (examples include KOH microscopy, fungal culture, PAS histology, and PCR/molecular testing).
    Acceptable methodsKOH preparation, fungal culture of subungual material, periodic acid–Schiff (PAS) staining of nail clippings, and PCR-based NAATs (choice depends on need for species ID and resources).
    Specimen guidanceObtain subungual debris and multiple nail clippings from the most proximal area of onycholysis; clean the nail with 70% isopropyl alcohol prior to collection as recommended by guidelines cited in the policy.